LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

NVS

122.92

-0.28%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

NVS

122.92

-0.28%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

NVS

122.92

-0.28%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

NVS

122.92

-0.28%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

NVS

122.92

-0.28%↓

Search

Bio-Techne Corp

Cerrado

SectorSalud

51.66 0.23

Resumen

Variación precio

24h

Actual

Mínimo

50.94

Máximo

51.98

Métricas clave

By Trading Economics

Ingresos

-40M

-18M

Ventas

783K

317M

P/B

Media del Sector

117.63

35.664

BPA

0.53

Rentabilidad por dividendo

0.59

Margen de beneficio

-5.577

Empleados

3,100

EBITDA

-61M

6.4M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+27.86% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.59%

3.12%

Próximas Ganancias

29 oct 2025

Fecha Próximo Dividendo

21 nov 2025

Próxima Fecha de Ex Dividendo

10 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-473M

8.4B

Apertura anterior

51.43

Cierre anterior

51.66

Noticias sobre sentimiento de mercado

By Acuity

27%

73%

82 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

Bio-Techne Corp Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

16 sept 2025, 17:03 UTC

Principales Movimientos del Mercado

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

16 sept 2025, 16:49 UTC

Principales Movimientos del Mercado
Adquisiciones, fusiones, absorciones

GD Culture Shares Drop After Deal for Pallas Capital

16 sept 2025, 16:11 UTC

Principales Movimientos del Mercado

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

16 sept 2025, 23:40 UTC

Charlas de Mercado

Nikkei May Decline as Yen Strengthens -- Market Talk

16 sept 2025, 23:34 UTC

Charlas de Mercado

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

16 sept 2025, 23:20 UTC

Charlas de Mercado

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

16 sept 2025, 21:10 UTC

Adquisiciones, fusiones, absorciones

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

16 sept 2025, 20:51 UTC

Charlas de Mercado

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

16 sept 2025, 20:50 UTC

Charlas de Mercado

Energy & Utilities Roundup: Market Talk

16 sept 2025, 20:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Basic Materials Roundup: Market Talk

16 sept 2025, 20:25 UTC

Ganancias

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

16 sept 2025, 20:24 UTC

Ganancias

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

16 sept 2025, 19:19 UTC

Charlas de Mercado

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

16 sept 2025, 18:52 UTC

Charlas de Mercado

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

16 sept 2025, 18:44 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

16 sept 2025, 18:44 UTC

Charlas de Mercado

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

16 sept 2025, 18:40 UTC

Adquisiciones, fusiones, absorciones

Details Emerge on U.S.-China TikTok Deal -- WSJ

16 sept 2025, 18:38 UTC

Charlas de Mercado

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

16 sept 2025, 18:19 UTC

Charlas de Mercado

Gold Settles at New High Ahead of Fed Decision -- Market Talk

16 sept 2025, 18:01 UTC

Charlas de Mercado

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

16 sept 2025, 17:34 UTC

Charlas de Mercado

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

16 sept 2025, 16:53 UTC

Ganancias

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

16 sept 2025, 16:20 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Basic Materials Roundup: Market Talk

16 sept 2025, 16:15 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Global Commodities Roundup: Market Talk

16 sept 2025, 16:09 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Global Energy Roundup: Market Talk

16 sept 2025, 16:09 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

16 sept 2025, 15:35 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

16 sept 2025, 15:35 UTC

Charlas de Mercado

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

16 sept 2025, 15:22 UTC

Charlas de Mercado

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

16 sept 2025, 15:21 UTC

Charlas de Mercado

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Comparación entre iguales

Cambio de precio

Bio-Techne Corp Esperado

Precio Objetivo

By TipRanks

27.86% repunte

Estimación a 12 meses

Media 66 USD  27.86%

Máximo 75 USD

Mínimo 53 USD

De acuerdo con 13 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Bio-Techne Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

13 ratings

10

Comprar

3

Mantener

0

Vender

Puntuación técnica

By Trading Central

49.67 / 50.24Soporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Strong Bearish Evidence

Sentimiento

By Acuity

82 / 371 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
help-icon Live chat